Provided by Tiger Trade Technology Pte. Ltd.

Arcutis Biotherapeutics Inc.

23.95
+0.56502.42%
Volume:904.70K
Turnover:21.60M
Market Cap:2.99B
PE:111.16
High:24.18
Open:23.63
Low:23.59
Close:23.38
52wk High:31.77
52wk Low:16.57
Shares:125.07M
Float Shares:111.18M
Volume Ratio:0.52
T/O Rate:0.81%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.2154
EPS(LYR):-0.1269
ROE:15.86%
ROA:5.09%
PB:13.58
PE(LYR):-188.75

Loading ...

Arcutis Biotherapeutics Grants 143,500 RSUs, 37,000 Stock Options to New Hires Under Inducement Plan

Reuters
·
Aug 08

Arcutis Biotherapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Aug 08

Did Profitability, Higher 2026 Guidance, and New Commercial Leadership Just Recast Arcutis Biotherapeutics' (ARQT) Investment Narrative?

Simply Wall St.
·
Aug 06

Arcutis Biotherapeutics is Maintained at Buy by Guggenheim

Dow Jones
·
Aug 06

Arcutis Biotherapeutics (ARQT) Gets a Buy from Mizuho Securities

TIPRANKS
·
Aug 06

Arcutis Biotherapeutics, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

Arcutis Biotherapeutics Announces Key Commercial Leadership Changes

TIPRANKS
·
Aug 06

Arcutis Q2 Revenue Rises on Demand for Zoryve, Lifts 2026 Sales Outlook

Reuters
·
Aug 06

Arcutis Biotherapeutics Q2 EPS $0.11 Beats $0.03 Estimate, Sales $129.861M Beat $118.852M Estimate

Benzinga Earnings
·
Aug 06

Arcutis Q2 Net Income Turns to USD 15 Million; Revenue Rises 59% Year over Year to USD 129.9 Million

Reuters
·
Aug 06

Arcutis Biotherapeutics: Raised Net Product Sales Guidance for the Full Year 2026 from $480 Million–$495 Million to $525 Million–$540 Million

THOMSON REUTERS
·
Aug 06

Arcutis Biotherapeutics Q2 Operating Expenses USD 113.432 Million

THOMSON REUTERS
·
Aug 06

Arcutis Biotherapeutics Inc Expected to Post Earnings of 4 Cents a Share - Earnings Preview

Reuters
·
Aug 04

Earning Preview: Arcutis Biotherapeutics Inc. this quarter’s revenue is expected to increase by 61.29%, and institutional views are mostly bullish

Earnings Agent
·
Jul 29

Arcutis Biotherapeutics Director Christopher Peetz Files Initial Beneficial Ownership Statement

Reuters
·
Jul 18

Arcutis Biotherapeutics Director Howard G. Welgus Disposes of 4,730 Common Shares Worth $127,269.30

Reuters
·
Jul 18

Arcutis Appoints Mirum CEO Chris Peetz to Board

Reuters
·
Jul 16

Arcutis Expands Board of Directors with Appointment of Chris Peetz

THOMSON REUTERS
·
Jul 16

Arcutis Biotherapeutics Schedules Second-quarter Results Conference Call

Reuters
·
Jul 16

Attovia Therapeutics Appoints John W. Smither to Board of Directors

THOMSON REUTERS
·
Jul 15